The flavonoid apigenin ameliorates cisplatin-induced nephrotoxicity through reduction of p53 activation and promotion of PI3K/Akt pathway in human renal proximal tubular epithelial cells

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Ju, Sung Min ^a   Kang, Jun Gue ^a   Bae, Jun Sang ^b   Pae, Hyun Ock ^c   Lyu, Yeoung Su ^a   Jeon, Byung Hun ^a  

^a Wonkwang University   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c Wonkwang University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; CASPASE 3; CISPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION;

EID: 84930622709     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/186436     Document Type: Article

References (40)

1. L. Kelland, "The resurgence of platinum-based cancer chemotherapy," Nature Reviews Cancer, vol. 7, no. 8, pp. 573-584, 2007.
2. K. Barabas, R. Milner, D. Lurie, and C. Adin, "Cisplatin: a review of toxicities and therapeutic applications," Veterinary and Comparative Oncology, vol. 6, no. 1, pp. 1-18, 2008.
3. M. H. Hanigan and P. Devarajan, "Cisplatin nephrotoxicity: molecular mechanisms," Cancer Terapy, vol. 1, pp. 47-61, 2003.
4. S. R. McWhinney, R. M. Goldberg, and H. L. McLeod, "Platinum neurotoxicity pharmacogenetics," Molecular Cancer Terapeutics, vol. 8, no. 1, pp. 10-16, 2009.
5. L. P. Rybak, "Mechanisms of cisplatin ototoxicity and progress in otoprotection," Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 15, no. 5, pp. 364-369, 2007.
6. L. X. Cubeddu, "Mechanisms by which cancer chemotherapeu-tic drugs induce emesis," Seminars in Oncology, vol. 19, no. 6, pp. 2-13, 1992.
7. P. E. Kintzel, "Anticancer drug-induced kidney disorders: incidence, prevention and management," Drug Safety, vol. 24, no. 1, pp. 19-38, 2001.
8. N. Pabla and Z. Dong, "Cisplatin nephrotoxicity: mechanisms and renoprotective strategies," Kidney International, vol. 73, no. 9, pp. 994-1007, 2008.
9. M. Jiang, Q. Wei, N. Pabla et al., "Efects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity," Biochemical Pharmacology, vol. 73, no. 9, pp. 1499-1510, 2007
10. S. M. Ju, H. O. Pae, W. S. Kim, D. G. Kang, H. S. Lee, and B. H. Jeon, "Role of reactive oxygen species in p53 activation during cisplatin-induced apoptosis of rat mesangial cells," European Review for Medical and Pharmacological Sciences, vol. 18, no. 8, pp. 1135-1141, 2014.
11. C. Manach, A. Scalbert, C. Morand, C. Rémésy, and L. Jimenez, "Polyphenols: Food sources and bioavailability," The American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 727-747, 2004.
12. Y.-J. Surh, "Cancer chemoprevention with dietary phytochemi-cals," Nature Reviews Cancer, vol. 3, no. 10, pp. 768-780, 2003.
13. I. Arsic, V. Tadic, D. Vlaovic et al., "Preparation of novel apigenin-enriched, liposomal and non-liposomal, antiinfammatory topical formulations as substitutes for corticosteroid therapy," Phytotherapy Research, vol. 25, no. 2, pp. 228-233, 2011.
14. J. P. V. Singh, K. Selvendiran, S. Mumtaz Banu, R. Padmavathi, and D. Sakthisekaran, "Protective role of Apigenin on the status of lipid peroxidation and antioxidant defense against hepato-carcinogenesis in Wistar albino rats," Phytomedicine, vol. 11, no. 4, pp. 309-314, 2004.
15. S. K. Ha, P. Lee, J. A. Park et al., "Apigenin inhibits the production of NO and PGE2 in microglia and inhibits neuronal cell death in a middle cerebral artery occlusion-induced focal ischemia mice model," Neurochemistry International, vol. 52, no. 4-5, pp. 878-886, 2008.
16. M. C. W. Myhrstad, H. Carlsen, O. Nordström, R. Blomhof, and J. Ø. Moskaug, "Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter," Free Radical Biology and Medicine, vol. 32, no. 5, pp. 386-393, 2002.
17. H. Wei, L. Tye, E. Bresnick, and D. F. Birt, "Inhibitory efect of apigenin, a plant favonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice," Cancer Research, vol. 50, no. 3, pp. 499-502, 1990.
18. P. Kaur, S. Shukla, and S. Gupta, "Plant favonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study," Carcinogenesis, vol. 29, no. 11, pp. 2210-2217, 2008.
19. E. J. Choi and G.-H. Kim, "Apigenin causes G2/M arrest associated with the modulation of p21 lp and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells," The Journal of Nutritional Biochemistry, vol. 20, no. 4, pp. 285-290, 2009.
20. A. Das, N. L. Banik, and S. K. Ray, "Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to favonoids," International Journal of Cancer, vol. 119, no. 11, pp. 2575-2585, 2006.
21. S. Gupta, F. Afaq, and H. Mukhtar, "Selective growth-inhibitory cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells," Biochemical and Biophysical Research Communications, vol. 287, no. 4, pp. 914-920, 2001.
22. L.-P. Chan, T.-H. Chou, H.-Y Ding et al., "Apigenin induces apoptosis via tumor necrosis factor receptor-and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fuorouracil and cisplatin," Biochimica et Biophysica Acta-General Subjects, vol. 1820, no. 7, pp. 1081-1091, 2012.
23. Y. Y. Xu, T. T. Wu, S. H. Zhou et al., "Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study," International Journal of Clinical and Experimental Pathology, vol. 7, no. 7, pp. 3938-3947, 2014.
24. A. T. M. Vaughan, C. J. Betti, and M. J. Villalobos, "Surviving apoptosis," Apoptosis, vol. 7, no. 2, pp. 173-177, 2002.
25. P. Decker and S. Muller, "Modulating poly (ADP-ribose) poly-merase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress," Current Pharmaceutical Biotechnology, vol. 3, no. 3, pp. 275-283, 2002.
26. S. R. Datta, A. Brunet, and M. E. Greenberg, "Cellular survival: a play in three akts," Genes & Development, vol. 13, no. 22, pp. 2905-2927, 1999.
27. R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, and M. D. Waterfeld, "Cellular function of phosphoinositide 3-kinase: implications for development, immunity, homeostasis, and cancer," Annual Review of Cell and Developmental Biology, vol. 17, pp. 615-675, 2001.
28. J. Luo, B. D. Manning, and L. C. Cantley, "Targeting the PI3K-Akt pathway in human cancer: rationale and promise," Cancer Cell, vol. 4, no. 4, pp. 257-262, 2003.
29. Y. Ogawara, S. Kishishita, T. Obata et al., "Akt enhances Mdm2-mediated ubiquitination and degradation of p53," The Journal of Biological Chemistry, vol. 277, no. 24, pp. 21843-21850, 2002.
30. S. Solmaz, A. Adan Gokbulut, B. Cincin et al., "Terapeutic potential of apigenin, a plant favonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells," Nutrition and Cancer, vol. 66, no. 4, pp. 599-612, 2014.
31. D. Maggioni, W. Garavello, R. Rigolio, L. Pignataro, R. Gaini, and G. Nicolini, "Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis," International Journal of Oncology, vol. 43, no. 5, pp. 1675-1682, 2013.
32. D. Arango, A. Parihar, F. A. Villamena et al., "Apigenin induces DNA damage through the PKCα-dependent activation of ATM and H2AX causing down-regulation of genes involved in cell cycle control and DNA repair," Biochemical Pharmacology, vol. 84, no. 12, pp. 1571-1580, 2012.
33. H.-F. Lu, Y.-J. Chie, M.-S. Yang et al., "Apigenin induces apop-tosis in human lung cancer H460 cells through caspase-and mitochondria-dependent pathways," Human & Experimental Toxicology, vol. 30, no. 8, pp. 1053-1061, 2011.
34. M. Cheung and J. R. Testa, "Diverse mechanisms of AKT pathway activation in human malignancy," Current Cancer Drug Targets, vol. 13, no. 3, pp. 234-244, 2013.
35. R. Honda, H. Tanaka, and H. Yasuda, "Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53," FEBS Letters, vol. 420, no. 1, pp. 25-27, 1997.
36. Z. K. Yu, R. K. Geyer, and C. G. Maki, "MDM2-dependent ubi-quitination of nuclear and cytoplasmic P53," Oncogene, vol. 19, no. 51, pp. 5892-5897, 2000.
37. M. Fraser, B. M. Leung, X. Yan, H. C. Dan, J. Q. Cheng, and B. K. Tsang, "p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells," Cancer Research, vol. 63, no. 21, pp. 7081-7088, 2003.
38. M. R. Abedini, E. J. Muller, R. Bergeron, D. A. Gray, and B. K. Tsang, "Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein," Oncogene, vol. 29, no. 1, pp. 11-25, 2010.
39. A. Skladanowski, P. Bozko, M. Sabisz, and A. K. Larsen, "Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-defcient cells with strong survival signaling: implications for cancer therapy," Cell Cycle, vol. 6, no. 18, pp. 2268-2275, 2007.
40. G. Zhang, M. Li, X. Zhu, Y. Bai, and C. Yang, "Knockdown of Akt sensitizes osteosarcoma cells to apoptosis induced by cis-platin treatment," International Journal of Molecular Sciences, vol. 12, no. 5, pp. 2994-3005, 2011.